Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Avenue Therapeutics Inc (ATXI)

Avenue Therapeutics Inc (ATXI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 182,397
  • Shares Outstanding, K 16,703
  • Annual Sales, $ 0 K
  • Annual Income, $ -25,910 K
  • 60-Month Beta 0.20
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 44.38

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.10
  • Number of Estimates 2
  • High Estimate -0.07
  • Low Estimate -0.13
  • Prior Year -0.14
  • Growth Rate Est. (year over year) +28.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.55 +3.41%
on 09/28/20
12.34 -11.59%
on 09/14/20
-0.45 (-3.96%)
since 08/28/20
3-Month
9.21 +18.42%
on 07/14/20
12.34 -11.59%
on 09/14/20
+0.17 (+1.58%)
since 06/26/20
52-Week
4.96 +119.85%
on 10/17/19
12.34 -11.59%
on 09/14/20
+5.09 (+87.46%)
since 09/27/19

Most Recent Stories

More News
Avenue Therapeutics Announces Publication of a Review of IV Tramadol

Avenue Therapeutics, Inc. (NASDAQ: ATXI) ("Avenue"), a company focused on the development of intravenous ("IV") tramadol for the U.S. market, today announced that a publication entitled "IV tramadol: A...

ATXI : 10.91 (-0.09%)
FBIO : 3.94 (-2.48%)
Avenue Therapeutics (ATXI) Misses Earnings Estimates in Q2

Avenue Therapeutics (ATXI) reports a wider-than-expected loss in the second quarter of 2021.

BLRX : 1.6500 (+5.77%)
PCRX : 59.37 (+0.78%)
ESALY : 91.8000 (+1.94%)
ATXI : 10.91 (-0.09%)
Avenue Therapeutics Reports Second Quarter 2020 Financial Results and Recent Corporate Highlights

Avenue Therapeutics, Inc. (NASDAQ: ATXI) ("Avenue"), a company focused on the development of intravenous ("IV") tramadol for the U.S. market, today reported financial results and recent corporate highlights...

ATXI : 10.91 (-0.09%)
FBIO : 3.94 (-2.48%)
Fortress Biotech Announces Virtual Two-Day Corporate Access Summit Hosted by B. Riley FBR on Tuesday, August 18 and Wednesday, August 19, 2020

Fortress Biotech, Inc. (NASDAQ: FBIO) ("Fortress"), an innovative revenue-generating company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and...

ATXI : 10.91 (-0.09%)
CKPT : 2.62 (-6.76%)
FBIO : 3.94 (-2.48%)
What's in Store for Avenue Therapeutics (ATXI) in Q2 Earnings?

Avenue Therapeutics' (ATXI) sole pipeline candidate, tramadol, is under review. With lower clinical activities, operating expenses are likely to have declined during the second quarter.

TBIO : 13.19 (+0.46%)
PCRX : 59.37 (+0.78%)
ACRX : 1.5300 (+2.68%)
ATXI : 10.91 (-0.09%)
Alpine Begins Dosing in Phase I Study for Advanced Malignancies

Alpine (ALPN) doses the first patient in the phase I NEON-1 study evaluating its pipeline candidate ALPN-202 for treating patients with advanced malignancies.

ABBV : 87.28 (+1.22%)
ALDX : 7.17 (+4.98%)
ALPN : 8.48 (+3.67%)
ATXI : 10.91 (-0.09%)
Veru (VERU) Soars: Stock Adds 6.9% in Session

Veru (VERU) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

VERU : 2.64 (+2.33%)
ATXI : 10.91 (-0.09%)
Avenue Therapeutics, Inc. (ATXI) Upgraded to Strong Buy: Here's What You Should Know

Avenue Therapeutics, Inc. (ATXI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

ATXI : 10.91 (-0.09%)
New Strong Buy Stocks for June 24th

New Strong Buy Stocks for June 24th

VIVO : 16.61 (+0.67%)
USNA : 74.24 (-0.68%)
SNX : 131.50 (+2.73%)
BOXL : 1.6200 (-2.41%)
ATXI : 10.91 (-0.09%)
Applied Genetic (AGTC) Soars: Stock Adds 6.1% in Session

Applied Genetic (AGTC) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

AGTC : 4.91 (+0.82%)
ATXI : 10.91 (-0.09%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade ATXI with:

Business Summary

Avenue Therapeutics, Inc. is a specialty pharmaceutical company. It acquires, licenses, develops and commercializes products principally for use in the acute/intensive care hospital setting. Avenue Therapeutics, Inc. is based in New York, United States.

See More

Key Turning Points

2nd Resistance Point 11.55
1st Resistance Point 11.23
Last Price 10.91
1st Support Level 10.57
2nd Support Level 10.23

See More

52-Week High 12.34
Last Price 10.91
Fibonacci 61.8% 9.52
Fibonacci 50% 8.65
Fibonacci 38.2% 7.78
52-Week Low 4.96

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar